Biology subjects

Burleigh, S. M.

Publications and source records attributed to Burleigh, S. M..

3 recordsLinked to original sources

bioRxiv2026

Rett syndrome lifespan extension in mice via AI-guided ADAR editing

Rett syndrome is a severe neurodevelopmental disorder primarily caused by mutations in the MECP2 gene. A significant subset of severe cases are driven by nonsense mutations that generate premature stop codons, leading to loss of functional MeCP2 protein. Here, we describe a novel therapeutic strategy that uses endogenous adenosine deaminase acting on RNA (ADAR) enzymes to correct the R168X mutation at the RNA level. Using generative artificial intelligence trained on large empirical datasets, we engineered guide RNAs (gRNAs) that recruit endogenous ADAR to convert the mutant stop codon (UGA) into a tryptophan (UGG) to restore full-length MeCP2. Once incorporated into an optimized expression system based on endogenous small nuclear RNA regulatory elements and packaged into adeno-associated virus, these gRNAs enabled precise RNA editing at the target site with minimal off-target activity across the transcriptome while restoring full-length MeCP2 protein expression in patient-derived induced pluripotent stem cell neurons. Delivered intravenously to an R168X mouse model, the gRNAs achieved ~70% targeted RNA editing and substantially restored MeCP2 throughout the brain resulting in markedly improved Rett-like phenotypes and significantly extended lifespan. These findings demonstrate that AI-guided ADAR-mediated RNA editing is a precise and efficient technology for correcting nonsense mutations, with therapeutic potential for Rett syndrome and other genetic diseases.

neuroscience↗

bioRxiv2025

Helix: a structure-aware deep learning model for accurate prediction of A-to-I RNA editing by endogenous ADARs

Adenosine deaminase acting on RNA (ADAR) converts adenosine to inosine within double-stranded RNA (dsRNA) and can be co-opted for therapeutic RNA editing by introducing dsRNA substrates in trans using programmable guide RNAs (gRNAs). However, ADARs natural promiscuity necessitates sophisticated gRNA designs to achieve efficient and specific editing. Here we present Helix, a predictive model that achieves highly accurate, zero-shot per-adenosine editing predictions for any target sequence. Helixs performance arises from two architectural choices: a transformer framework that scales effectively with increasing and imbalanced training data; and a structure-aware attention mechanism that incorporates predicted RNA secondary structure, a key determinant of ADAR activity. Helixs predictive accuracy enables seamless integration with DeepREAD, our previously reported generative model, in a noisy-student distillation framework termed DeepHelix. This workflow supports both zero-shot gRNA design and the generation of complex, constraint-based designs. We demonstrate DeepHelixs utility by designing gRNAs that efficiently edit a therapeutically relevant adenosine and by leveraging its flexible design space to engineer species cross-reactive gRNAs to accelerate pre-clinical development.

bioengineering↗

bioRxiv2024

A Novel Engineered U7 Small Nuclear RNA Scaffold Greatly Increases in vitro and in vivo ADAR-Mediated Programmable RNA Base Editing

Custom RNA base editing using the endogenous human Adenosine Deaminase Acting on RNA (ADAR) enzyme presents a promising approach for precision therapeutics, alleviating concerns of permanent DNA damage or immunogenicity from1 foreign bacterial proteins such as CRISPR/Cas. ADAR can be directed to act on therapeutic RNA targets by antisense guide RNAs (gRNAs) that create a substrate for ADARs adenosine-to-inosine (effectively A-to-G) deamination activity. Delivery of gRNAs via a DNA expression construct provided by Adeno-Associated Virus (AAV) might allow life-long duration of the therapy. However, a major challenge for RNA editing using gene-encoded gRNAs and endogenous levels of ADAR is achieving sufficient gRNA activity inside cells, especially in therapeutic situations where AAV delivery may provide as low as one viral genome per cell. Here we show that embedding antisense gRNAs into a U7 small nuclear RNA (snRNA) framework and adding hnRNP A1 binding domains greatly increases the efficiency of custom RNA editing. This increased editing efficiency allows for detectable RNA editing from a single genomic insertion of gRNA construct per cell, which enabled a pooled library screen of 750+ gRNA variations to further improve the SmOPT U7 hairpin system. The screen revealed critical residues responsible for RNA editing and generated new SmOPT and U7 hairpin variants that further boosted RNA editing. The final design, combined with an improved synthetic U7 promoter, resulted in up to 76% targeted editing with a single integrated copy of construct per cell, representing a 10- to 100-fold increase over existing circular gRNA approaches. Using systemic in vivo AAV delivery, we achieved an unprecedented 75% RNA editing in the total brain of a mouse model of Hurler syndrome. Our novel SmOPT U7 system also improved published antisense oligos for DMD exon skipping, currently in clinical trials, by up to 25-fold in differentiated myoblasts, and therefore represents a universal scaffold for ADAR-based RNA editing as well as other antisense RNA therapies.

bioengineering↗